Answers are grounded in this paper and cite their sources.
Q What are the nursing considerations for patients with axillary insertion of an intra-aortic balloon pump?A Brandi Holcomb, MSN, APRN, AGACNP-BC, CCRN, replies:The intra-aortic balloon pump (IABP) is a mechanical hemodynamic support device that uses counterpulsation to provide temporary circulatory assistance. An IABP is used to manage cardiogenic shock, refractory unstable angina, acute myocardial infarction, and refractory or intractable ventricular tachycardia. The device may also be used to support patients before and after cardiac surgery and to serve as a bridge to advanced therapies such as a left ventricular assist device or transplant. Additional indications include acute mitral valve regurgitation due to papillary rupture, ventricular septal rupture, as an adjunct to other ventricular assist devices, and failed percutaneous coronary intervention.1 An IABP should be avoided in patients with aortic dissection, significant aortic valve insufficiency, or thoracic aneurysms.1Counterpulsation is the fundamental principle underlying the IABP. Inflating and deflating the balloon in synchrony with the heart rate help augment diastolic blood pressure and increase coronary and cerebral arterial perfusion, thereby boosting myocardial oxygen delivery.1 During diastole, the IABP inflates and displaces blood from the ascending aorta while increasing diastolic pressure in the aortic root. During systole, the IABP deflates, reducing afterload, increasing stroke volume, and decreasing myocardial oxygen consumption and workload.2 Volume shifting of approximately 40 mL per heartbeat by the IABP increases left ventricular stroke volume and cardiac output by up to 1 L/min,2 with the most significant increases seen in patients with severely reduced cardiac output.The initial design of an IABP was for transfemoral placement; however, the traditional approach may introduce related complications. Because of the nature of femoral access, prolonged use of an IABP has been associated with infection, peripheral artery complications, and restricted mobility.3 A significant limitation of a femorally placed IABP is the ambulatory restriction that promotes deconditioning, particularly in situations requiring prolonged circulatory support. Therefore, the IABP is frequently removed after a few days of therapy, depriving patients of prolonged mechanical hemodynamic support.An attractive alternative is axillary arterial access for IABP placement. This technique was initially developed for patients with aortoiliac occlusive disease. A subclavian artery approach to IABP insertion is an alternative to a femoral artery IABP, allowing patients to be ambulatory to avoid deconditioning. The technique of transthoracic IABP insertion predominantly uses a short polyethylene terephthalate (Dacron; DuPont) conduit to enable the placement of the IABP in the ascending aorta or the axillary or subclavian artery.3 This procedure is performed under general anesthesia in an operating room suite.The refined technique allows patients to have an IABP inserted percutaneously via the upper extremity in the cardiac catheterization laboratory by either an interventional cardiologist or a cardiac surgeon.4 This procedure uses a direct axillary artery percutaneous stick and guidewire. A regular IABP catheter and console are used. If the patient is ambulatory, careful consideration must be given to securing the device to prevent migration. Current IABP catheters are longer than required for transaxillary use, leading to questions about securing the excess length.4The trans–brachial artery insertion method is safe and effective in patients with unstable coronary artery disease who require urgent coronary artery bypass graft surgery. Furthermore, multiple studies have demonstrated the effectiveness of ambulatory IABP placement in patients waiting for advanced therapies for heart failure, such as left ventricular assist device implantation or heart transplant.2 Percutaneous transaxillary access has evolved as an approach for prolonged mechanical hemodynamic support as a bridge to target therapy. Additionally, in many centers the transaxillary process for placement of the IABP has been the primary access method for patients with occlusive peripheral artery disease.Two metallic markers at each end of the IABP aid in placing the device under fluoroscopic guidance and in subsequent radiographic monitoring of the device position. The IABP is placed distal to the left subclavian artery origin and proximal to the renal arteries. The proximal marker is radiographically positioned 2 to 3 cm distal to the origin of the left subclavian artery or 2 cm above the carina. Depending on the degree of collimation, the distal metallic marker may not be visualized on a chest radiograph.5The most frequent minor adverse events with an IABP inserted through the axillary approach are migration (30%), hematoma (5%), infection (2%), and subclavian arterial thrombosis (1%).5 Interestingly, evidence supports minimal distal thromboembolic events with the subclavian IABP approach, making it appear safer than femoral insertion.Malposition of the IABP is a complication that is more common with transaxillary access; however, the device can be repositioned either at the bedside with ultrasound or portable C-arm guidance or in the cardiac catheterization laboratory under fluoroscopy.5 The axillary artery is more prone to injury during sheath insertion because of the higher elasticity of the vessel, and the anatomical location poses a challenge to manual compression at the puncture site, placing the patient at higher risk of hemorrhagic shock.6As previously mentioned, malposition and migration of an axillary IABP are the more common complications of this method of placement. The lack of evidence for appropriate securement makes a simple answer to the question a challenge. In the absence of research findings, expert opinions may be the best alternative; although these constitute one of the lowest levels of evidence, they are foundational to clinical practice. With a multidisciplinary team approach, everyone on the team should be comfortable with management of the access site, including avoiding dressings that might lead to a breach in the sterile sleeve when changed.When the patient is ambulatory, securing the device is important to prevent migration. Securing catheters to the upper arm solely with an occlusive dressing should be avoided, as movement will lead to catheter migration, which is challenging to correct. Foley catheter stabilization devices (StatLock; Bard) can be used to secure the catheter against movement. The sheath and IABP catheter should be sutured, secured with a stabilization device at the hub, and dressed with an occlusive chlorhexidine gluconate dressing (Tegaderm; 3M).5 Typically, 1 securement device can be used at the hub; however, dual securement devices can be used in a fashion similar to that of a pulmonary artery catheter system, with 1 at the hub and the second more distal to the insertion site. As stated previously, the use of occlusive dressings is recommended.Lack of evidence for appropriate securement of an IABP makes it difficult to provide a simple answer to the question. To ensure safe patient care, critical care nurses should have training in IABP use that builds their familiarity and expertise with anatomical placement, mechanics, hemodynamic response, and possible complications. A solid understanding of hemodynamics is necessary for accurate assessment and rapid intervention in cases of subtle or unexpected changes. Similarly, understanding of correct placement is essential to be able to recognize device malposition. Using a collaborative, interprofessional team approach and ensuring that everyone on the team is comfortable with management of the access site are important for success.
No takes yet. Share an insight, caveat, or question.
Brandi L. Holcomb (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: